EC regulation on conditional approval of medicinal products

 

New EU rules on conditional marketing authorisations for medicines for human use came into force at the beginning of April 2006, following a Regulation issued by the Commission on 29 March 2006 (No 507/2006).
 
Eurordis contributed to the shaping of this important regulation by submitting comments to the Commission in Jan. 2005 on the first draft regulation on conditional approval for medicinal products.
 
The regulation is of particular importance to rare diseases and orphan drugs. Conditional approval addresses situations where an urgent public health need exists, and a drug in development promises significant health benefits, but full safety or efficacy testing has not been completed. Conditional approval aims at speeding the product to market.
 
In a situation of conditional approval, the manufacturer, or "marketing authorisation holder" is committed to fulfil post-marketing obligations to obtain a definitive authorisation, based on full safety research and testing, or the product may be withdrawn from the market.

 

 
 
La voz de los pacientes de enfermedades raras en EuropaEURORDIS La voz internacional de las personas que tienen enfermedades rarasRare Disease International Reuniendo a pacientes, familiares y expertos para compartir experiencias en un foro moderado en distintos idiomas. RareConnect El Programa Rare Barometer es una iniciativa de EURORDIS que realiza encuestas para transformar las experiencias de los pacientes con enfermedades raras en cifras que puedan compartirse con los responsables políticos.Rare Barometer Una campaña internacional de sensibilización que se celebra todos los años el último día de febrero, El Día de las Enfermedades Raras es una iniciativa de EURORDISRare Disease Day Únete al mayor grupo de partes interesadas en toda Europa, en la Conferencia Europea sobre Enfermedades Raras y Medicamentos Huérfanos que se celebra cada dos años. ECRD es una iniciativa de EURORDISEuropean Conference on Rare Diseases